Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients-Reference-Cited by-同舟云学术

Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients

Published:2020-06-19 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Arcangeli Silvia,Falcone Laura,Camisa Barbara,De Girardi Federica,Biondi Marta,Giglio Fabio,Ciceri Fabio,Bonini Chiara,Bondanza Attilio,Casucci Monica

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference52 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia;Park;N Engl J Med,2018

3. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia;Porter;Sci Transl Med.,2015

4. Clinical lessons learned from the first leg of the car T cell journey;Majzner;Nat Med.,2019

5. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen receptor-modified T cells after failure of ibrutinib;Turtle;J Clin Oncol Sep,2017

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights;Frontiers in Immunology;2024-09-05

2. Recent updates on allogeneic CAR-T cells in hematological malignancies;Cancer Cell International;2024-09-03

3. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies;ImmunoTargets and Therapy;2024-08

4. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma;Blood Advances;2024-07-31

5. Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence;Cureus;2024-07-24